Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered perspective to ABC NewsOne about lecanemab, an experimental drug that in newly published data from a large, late-stage clinical trial has been shown to slow the rate of cognitive decline in early stage Alzheimer’s disease. The FDA still needs to approve the drug.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH